Developmental Therapeutics Program

摘要 发展治疗(DT)计划的目标是将基本的科学发现转化为临床 应用惠及所有年龄段的患者，提高集水区患者的生活质量 更远一点。成员在成人和儿科患者中开发、测试和研究新的疗法，这些患者具有固体和 并领导合作、多机构倡议以建立新的治疗方法 范例。DT方案通过改善获得护理的机会为集水区提供服务，并为下一个地区提供培训 一代癌症研究人员，专注于指导职业生涯早期的教职员工。DT程序增加了两个 前一次审查的重点：1)通过制定 在早期试验和疾病特定群体中，特别是那些已制定的群体中，孵化和优先考虑IIT 由被指导的成员。因此，干预治疗机构信托基金的应计项目从2016年的47项增加到 2020年将达到140人。2)加强临床前异种移植的开发，以促进免疫生物学/免疫治疗 发现号。DT资助的试点赠款生产孤儿疾病PDX，结直肠人性化模型(HM) 癌症，以及黑色素瘤的自体HM。DT有78名成员，代表18个部门和4所学校。 在NCI持有320万美元，在其他NIH持有200万美元，在其他同行审查资金中持有280万美元，同行增加了50% 审查研究经费，从2016年的540万美元增加到2020年的80万美元。自2016年以来，DT会员注册2688人 受试者共进行了641项干预治疗试验，增加了29%。DT成员发表1000篇同行评议 与癌症相关的论文，其中48%是合作的(15%是国际的；17%是内部的；16%都是)，24%是在期刊上发表的 有IF&GT；10.其中47%(47%)代表与其他NCI指定癌症的合作 中锋。科罗拉多大学癌症中心(UCCC)教育活动、培训/职业发展 活动和共享资源(SR)支持是DT资助试点赠款的优先事项的基础 强调“本土”疗法和从病床到床边的发现应用。这些投资导致了 成功的计划项目协作和跨UCCC的多PI资助。DT继续扩张 在UCCC内部以及与包括科罗拉多大学博尔德大学在内的主要合作伙伴之间建立多方利益攸关方伙伴关系 (UCB)、科罗拉多州立大学(CSU)、科罗拉多大学医院(UCH)、科罗拉多州儿童医院 和退伍军人管理局(VA)。UCH、CHCO和退伍军人管理局利用统一的共享机构 审查委员会，使一个强大和合规的系统，以应用DT计划的发现，并使患者在 集水区，同时简化了患者的通道。DT计划继续专注于推进 通过支持试点项目，利用美国国立卫生研究院研究评估和 商业化中心(REACH)计划，支持初创企业，并鼓励SBIR应用。最后， DT计划培养了战略性招聘，以加强其成员，以更好地整合儿科， 成人和同伴动物模型，影响整个癌症谱系的病人护理。

ABSTRACT The goal of the Developmental Therapeutics (DT) program is to translate basic scientific discovery to clinical application to benefit patients of all ages, improving the quality of life for patients in the catchment area and beyond. Members develop, test, and institute novel therapies in adult and pediatric patients with solid and hematologic malignancies and lead collaborative, multi-institutional initiatives to establish new treatment paradigms. The DT program serves the catchment area by improving access to care, and training the next generation of cancer researchers, focusing on mentoring early-career faculty. The DT program had two added points of focus as a result of the prior review: 1) enhancing investigator-initiated trials (IITs) by developing the IIT incubator and prioritizing IITs in early-phase trial and disease-specific groups, particularly those developed by mentored members. As a result, accruals to intervention treatment IITs increased 3-fold from 47 in 2016 to 140 in 2020. And 2) enhancing preclinical xenograft development to foster immunobiology/immunotherapy discovery. DT funded pilot grants producing orphan disease PDXs, humanized models (HM) for colorectal cancer, and an autologous HM in melanoma. With 78 members representing 18 departments and 4 schools, DT holds $3.2M in NCI, $2.0M in other NIH, and $2.8M in other peer-reviewed funding, a 50% increase in peer- reviewed research funding from $5.4M in 2016 to $8.0M in 2020. Since 2016, DT members enrolled 2688 subjects to 641 intervention treatment trials, an increase of 29%. DT members published 1000 peer-reviewed cancer-related papers, of which 48% were collaborative (15% inter-; 17% intra-; 16% both) and 24% in journals with an IF>10. Forty-seven percent (47%) of these represent collaborations with other NCI-designated cancer centers. University of Colorado Cancer Center (UCCC) educational activities, training/career enhancement activities, and shared resources (SRs) support are foundational to the DT's priorities of funding pilot grants that emphasize “homegrown” therapies and bench-to-bedside application of discoveries. These investments led to successful program project collaborations and multiple-PI funding across the UCCC. DT continues to expand multi-stakeholder partnerships within UCCC and with key partners, including the University of Colorado Boulder (UCB), Colorado State University (CSU), University of Colorado Hospital (UCH), Children's Hospital Colorado (CHCO), and the Veterans Administration (VA). UCH, CHCO, and the VA utilize a unified and shared Institutional Review Board, enabling a robust and compliant system to apply DT program discoveries and benefit patients in the catchment area, while streamlining access for patients. The DT program continues to focus on advancing novel compounds developed within UCCC by supporting pilot projects, using the NIH Research Evaluation and Commercialization Hubs (REACH) program, supporting start-ups, and encouraging SBIR applications. Lastly, the DT program has fostered strategic recruitments to strengthen its membership to better integrate pediatric, adult, and companion animal models, impacting patient care across the spectrum of cancer.